|
 | Up a level |
Wei, Yuxuan, Zhang, Yichen, Xu, Ziyue, Wang, Guoan, Zhou, Yue, Li, Huangqianyu, Shi, Luwen, Naci, Huseyin, Wagner, Anita K. and Guan, Xiaodong (2024) Cancer drug indication approvals in China and the United States: a comparison of approval times and clinical benefit, 2001–2020. The Lancet Regional Health - Western Pacific, 45. ISSN 2666-6065
Ivama-Brummell, Adriana M., Marciniuk, Fernanda L, Wagner, Anita K., Osorio-de-Castro, Claudia G. S., Vogler, Sabine, Mossialos, Elias 
ORCID: 0000-0001-8664-9297, Tavares-de-Andrade, Carla L. and Naci, Huseyin
(2023)
Marketing authorisation and pricing of FDA-approved cancer drugs in Brazil: a retrospective analysis.
The Lancet Regional Health - Americas, 22.
ISSN 2667-193X
Davis, Courtney, Wagner, Anita K., Salcher-Konrad, Maximilian ORCID: 0000-0002-5628-5266, Scowcroft, Henry, Mintzes, Barbara, Pokorny, Adrian M J, Lew, Jianhui and Naci, Huseyin
(2023)
Communication of anticancer drug benefits and related uncertainties to patients and clinicians: document analysis of regulated information on prescription drugs in Europe.
BMJ, 380.
e073711.
ISSN 0959-8138
Shahzad, Mahnum, Naci, Huseyin and Wagner, Anita K. (2023) Association between preapproval confirmatory trial initiation and conversion to traditional approval or withdrawal in the FDA accelerated approval pathway. JAMA, 329 (9). 760 - 761. ISSN 0098-7484
Zhang, Yichen, Naci, Huseyin, Wagner, Anita K., Xu, Ziyue, Yang, Yu, Zhu, Jun, Ji, Jiafu, Shi, Luwen and Guan, Xiaodong (2022) Overall survival benefits of cancer drugs approved in China from 2005 to 2020. JAMA network open, 5 (8). ISSN 2574-3805
Fu, Mengyuan, Naci, Huseyin, Booth, Christopher M., Gyawali, Bishal, Cosgrove, Austin, Toh, Sengwee, Xu, Ziyue, Guan, Xiaodong, Ross-Degnan, Dennis and Wagner, Anita K. (2021) Real-world use of and spending on new oral targeted cancer Drugs in the US, 2011-2018. JAMA Internal Medicine, 181 (12). 1596 - 1604. ISSN 2168-6106
Naci, Huseyin, Guan, Xiaodong, Woloshin, Steven, Xu, Ziyue and Wagner, Anita K. (2021) Communication of survival data in US Food and Drug Administration-approved labeling of cancer drugs. JAMA Internal Medicine, 181 (11). 1521 - 1522. ISSN 2168-6106
